Treatment of allergic conjunctivitis with ocular decongestants.
D000328:Adult; D000865:Antazoline / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000139:chemically induced / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009278:Naphazoline / Q000627:therapeutic use; D010632:Pheniramine / Q000627:therapeutic use; D011446:Prospective Studies; D011897:Random Allocation; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D003189:p-Methoxy-N-methylphenethylamine
D004338:Drug Combinations; D006634:Histamine H1 Antagonists; D014662:Vasoconstrictor Agents; D010632:Pheniramine; D003189:p-Methoxy-N-methylphenethylamine; D000865:Antazoline; D009278:Naphazoline